Herboxidiene and EGFR expression in A172 glioblastoma cells
Glioblastoma carries a five-year survival of about 10%, and EGFR amplification is one of the molecular criteria that define the disease in the 2021 WHO classification of central nervous system tumours. SF3b inhibitors, which displace the U2 snRNP from the intron branch point, suppress EGFR expression in lung adenocarcinoma cells by causing retention of EGFR intron 2. We asked whether the same…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
